Functional platelet defects in children with severe chronic ITP as tested with 2 novel assays applicable for low platelet counts

Blood (Impact Factor: 10.45). 01/2014; 123(10). DOI: 10.1182/blood-2013-08-519686
Source: PubMed


Immune thrombocytopenia (ITP) is an autoimmune disease with a complex heterogeneous pathogenesis and a bleeding phenotype that is not necessarily correlated to platelet count. In this study, the platelet function was assessed in a well-defined cohort of 33 pediatric chronic ITP patients. Since regular platelet function test cannot be performed in patients with low platelet counts, two new assays were developed to determine platelet function. First, the micro aggregation test measuring in platelets isolated from 10 ml whole blood, the platelet potential to form micro-aggregates in response to an agonist. Second, the platelet reactivity assay, measuring platelet reactivity to ADP, convulxin (CVX) and thrombin receptor activator peptide (TRAP) in only 150 µL unprocessed whole blood. Patients with a severe bleeding phenotype, demonstrated a decreased aggregation potential upon phorbol myristate acetate (PMA) stimulation, decreased platelet degranulation following ADP stimulation and a higher concentration of ADP and convulxin needed to activate the glycoprotein IIbIIIa complex compared to patients with a mild bleeding phenotype. In conclusion, here we have established two functional tests that allows for evaluation of platelet function in patients with extremely low platelet counts (<10(9)). These tests show that platelet function is related to bleeding phenotype in chronic ITP.

33 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective Platelet reactivity, platelet binding to monocytes and monocyte infiltration play a detrimental role in atherosclerotic plaque progression. We investigated whether platelet reactivity was associated with levels of circulating platelet-monocyte complexes (PMCs) and macrophages in human atherosclerotic carotid plaques. Methods Platelet reactivity was determined by measuring platelet P-selectin expression after platelet stimulation with increasing concentrations of adenosine diphosphate (ADP), in two independent cohorts: the Circulating Cells cohort (n = 244) and the Athero-Express cohort (n = 91). Levels of PMCs were assessed by flow cytometry in blood samples of patients who were scheduled for percutaneous coronary intervention (Circulating Cells cohort). Monocyte infiltration was semi-quantitatively determined by histological examination of atherosclerotic carotid plaques collected during carotid endarterectomy (Athero-Express cohort). Results We found increased platelet reactivity in patients with high PMCs as compared to patients with low PMCs (median (interquartile range): 4153 (1585–11267) area under the curve (AUC) vs. 9633 (3580–21565) AUC, P<0.001). Also, we observed increased platelet reactivity in patients with high macrophage levels in atherosclerotic plaques as compared to patients with low macrophage levels in atherosclerotic plaques (mean±SD; 8969±3485 AUC vs. 7020±3442 AUC, P = 0.02). All associations remained significant after adjustment for age, sex and use of drugs against platelet activation. Conclusion Platelet reactivity towards ADP is associated with levels of PMCs and macrophages in human atherosclerotic carotid plaques.
    PLoS ONE 08/2014; 9(8):e105019. DOI:10.1371/journal.pone.0105019 · 3.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Platelets are key cells in atherosclerosis and acute cardiovascular events. Platelet hyperreactivity and increased platelet-monocyte aggregation (PMA) are found in HIV-infected patients and may contribute to the excess cardiovascular risk. The integrase inhibitor raltegravir (RAL) has been associated with better residual viral suppression and reduction in inflammatory and coagulation biomarkers. The aim of our study was to investigate whether RAL-treated patients have reduced platelet reactivity and PMA. Design and methods: We performed a cross-sectional study involving 80 virologically suppressed adult HIV1-infected patients on a RAL-based (n = 25), nonnucleoside reverse transcriptase inhibitor (NNRTI)-based (n = 30) or a protease inhibitor based (n = 25) regimen and 30 healthy controls. Platelet reactivity was determined by measuring platelet P-selectin expression and the binding of fibrinogen to platelets to stimulation with two concentrations of ADP. PMA was determined by measuring the expression of the platelet marker CD42b on CD14 positive cells. Results: HIV-infected individuals had higher platelet reactivity and PMA than controls. RAL-treated individuals showed significantly lower P-selectin expression to stimulation with low (P = 0.026 vs. NNRTI and P = 0.005 vs. protease inhibitor group) and high-dose ADP (P = 0.009 vs. NNRTI and P = 0.003 vs. protease inhibitor group). A similar trend for was found for fibrinogen binding, although only the difference in P-selectin expression between RAL and protease inhibitor treated patients reached statistical significance (P = 0.038). PMA was also lower in the RAL group than in the NNRTI (P = 0.037) and protease inhibitor (P = 0.034) groups. Conclusion: Use of a RAL-based regimen was associated with a reduction in persistent HIV-induced platelet hyperreactivity and PMA compared with NNRTI and protease inhibitor based regimen.
    AIDS (London, England) 09/2014; 28(14):2091-2096. DOI:10.1097/QAD.0000000000000415 · 5.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Immune thrombocytopenia (ITP) patients with similarly low platelet counts differ in their tendency to bleed. To determine if differences in platelet function in ITP patients account for this variation in bleeding tendency, we conducted a single-center, cross-sectional study of pediatric patients with ITP. Bleeding severity (assessed by standardized bleeding score) and platelet function (assessed by whole blood flow cytometry) with and without agonist stimulation were evaluated in 57 ITP patients (median age 9.9 years). After adjustment for platelet count, higher levels of thrombin receptor activating peptide (TRAP)-stimulated percent P-selectin- and activated glycoprotein IIb-IIIa-positive platelets were significantly associated with a lower bleeding score while higher levels of immature platelet fraction, TRAP-stimulated platelet surface CD42b, unstimulated platelet surface P-selectin and platelet forward light scatter (FSC) were associated with a higher bleeding score. Thus, platelet function tests related to platelet age (immature platelet fraction, FSC) and activation through the PAR1 thrombin receptor (TRAP-stimulated P-selectin, activated GPIIb-IIIa, and CD42b), independent of platelet count, are associated with concurrent bleeding severity in ITP. These tests may be useful markers of future bleeding risk in ITP. Copyright © 2015 American Society of Hematology.
    Blood 07/2015; 126(7). DOI:10.1182/blood-2015-02-628461 · 10.45 Impact Factor


33 Reads
Available from